Sun Pharma Shares Surge 16% Following Organon Acquisition Announcement
Organon deal impact: Sun Pharma surges 16% in 10 days, nears record high
Business StandardImage: Business Standard
Sun Pharmaceutical Industries' shares surged 16% over the past 10 trading days, reaching a 52-week high of ₹1,885. This increase follows the announcement of its acquisition of Organon in an all-cash deal valued at $11.75 billion, expected to enhance Sun Pharma's global footprint and revenue significantly.
- 01Sun Pharma's stock rose 16% in 10 days, nearing its all-time high.
- 02The acquisition of Organon is valued at $11.75 billion.
- 03Analysts predict the deal will double Sun Pharma's revenue to $12 billion.
- 04The acquisition is expected to yield cost synergies of around $350 million.
- 05Brokerages have upgraded their target prices, with some suggesting a target of ₹2,300.
Advertisement
In-Article Ad
Shares of Sun Pharmaceutical Industries (Sun Pharma) have climbed 16% over the past 10 trading days, hitting a 52-week high of ₹1,885 amid a generally weak market. This surge follows the announcement on April 27, 2026, that the company will acquire Organon, a global healthcare firm, for $11.75 billion. The deal is projected to significantly enhance Sun Pharma's global presence, potentially positioning it among the top 25 pharmaceutical companies worldwide with a pro-forma revenue of $12.4 billion. Analysts expect the acquisition to bolster Sun Pharma's leadership in Women's Health and Biosimilars, while also expanding its innovative medicine portfolio. The acquisition is anticipated to generate cost synergies of approximately $350 million through improved procurement and manufacturing efficiencies. Brokerages have responded positively, with target prices for Sun Pharma's shares being revised upward, reflecting strong confidence in the company's future growth post-acquisition.
Advertisement
In-Article Ad
The acquisition is likely to enhance Sun Pharma's market position, potentially leading to increased job opportunities and economic growth in the pharmaceutical sector.
Advertisement
In-Article Ad
Reader Poll
Do you think the acquisition of Organon will benefit Sun Pharma in the long term?
Connecting to poll...
More about Sun Pharmaceutical Industries
Read the original article
Visit the source for the complete story.






